Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Robert Knight who wrote (678)	6/30/1998 9:54:00 PM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

that was it Robert and it was on the front page of IBD this AM:, thus the fall in AGPH and IMNR, the drugs were reported at the Conference. both PROMISE easier to follow drug-taking regimes than the prot-inhib's with 2x a day dosing only. both block key enzyme reverse transcriptase wich virus needs to take over Immune system cells. this in no way rules out REMUNE's role to continue to strengthen the Immunne system and to work in conjunction with these drugs or any other coming to market. and your right what a game is being played for this issue. still see the longer term support at 15 till proven otherwise, a lot of movement between firms after hours again. good luck. ar.